Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 11/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 2/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.31 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25001373 | 0.86 | CYP2D6 (0.41) | CYP2D6SMN1; SMN2ALDH1A1CYP3A4TSHR | |
| SCHEMBL22477427 | 0.83 | CYP2D6 (0.59) | CYP2D6SMN1; SMN2ALDH1A1CYP3A4TSHR | |
| SCHEMBL27349170 | 0.81 | TSHR (0.44) | CYP2D6SMN1; SMN2ALDH1A1CYP3A4TSHR | |
| SCHEMBL14498621 | 0.81 | GAA (0.41) | SMN1; SMN2ALDH1A1TSHRSLC6A2 | |
| SCHEMBL15495015 | 0.81 | GAA (0.41) | SMN1; SMN2ALDH1A1TSHRSLC6A2 | |
| SCHEMBL22477401 | 0.73 | CYP2D6 (0.41) | CYP2D6SMN1; SMN2ALDH1A1CYP3A4TSHR | |
| SCHEMBL18926689 | 0.73 | CYP2D6 (0.68) | CYP2D6SMN1; SMN2ALDH1A1CYP3A4TSHR | |
| SCHEMBL29324702 | 0.73 | CYP2D6 (0.37) | CYP2D6SMN1; SMN2TSHRCYP2C9 | |
| SCHEMBL26405491 | 0.73 | CYP2D6 (0.38) | CYP2D6SMN1; SMN2ALDH1A1CYP3A4SLC6A2 | |
| SCHEMBL25001374 | 0.72 | OPRM1 (0.35) | CYP2D6SMN1; SMN2TSHRMAPK1HIF1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230219986-A1 | NOVEL AMINOPYRIMIDINE EGFR INHIBITOR | QILU PHARMACEUTICAL CO., LTD. (CN) | 2023-07-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230219986-A1 | NOVEL AMINOPYRIMIDINE EGFR INHIBITOR | EGFR, ERBB2, ERBB4 | CYP2D6 2252/4885SMN1; SMN2 4575/4885ALDH1A1 2690/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.